Similarly, a study using cetuximab-resistant CRC cell lines reported that regorafenib overcomes primary and acquired resistance to anti-EGFR therapy by targeting the MAPK and AKT pathways51. This evidence concerns the gene EGFR and colorectal carcinoma.